Efficacy and Tolerability of Benzodiazepines versus Antidepressants in Anxiety Disorders: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Background: Placebo-controlled trials showed that both benzodiazepines (BDZ) and antidepressant drugs (AD) are effective in treating anxiety disorders. However, in the last years a progressive shift in the prescribing pattern from BDZ to newer AD has taken place. The aim of this systematic review and meta-analysis is to analyze whether controlled comparisons support such a shift. Methods: CINHAL, the Cochrane Library, MEDLINE, PubMed and Web of Science were searched from inception up to December 2012. A total of 22 studies met the criteria for inclusion. They were mostly concerned with tricyclic antidepressants (TCA; 18/22) and involved different anxiety disorders. In order to reduce clinical heterogeneity, only the 10 investigations that dealt with the comparison between TCA and BDZ in panic disorder were submitted to meta-analysis, whereas the remaining papers were individually summarized and critically examined. Results: According to the systematic review, no consistent evidence emerged supporting the advantage of using TCA over BDZ in treating generalized anxiety disorder (GAD), complex phobias and mixed anxiety-depressive disorders. Indeed, BDZ showed fewer treatment withdrawals and adverse events than AD. In panic disorder with and without agoraphobia our meta-analysis found BDZ treatments more effective in reducing the number of panic attacks than TCA (risk ratio, RR = 1.13; 95% CI = 1.01-1.27). Furthermore, BDZ medications were significantly better tolerated than TCA drugs, causing less discontinuation (RR = 0.40; 95% CI = 0.20-0.57) and side effects (RR = 0.41; 95% CI = 0.34-0.50). As to newer AD, BDZ trials resulted in comparable or greater improvements and fewer adverse events in patients suffering from GAD or panic disorder. Conclusions: The change in the prescribing pattern favoring newer AD over BDZ in the treatment of anxiety disorders has occurred without supporting evidence. Indeed, the role and usefulness of BDZ need to be reappraised.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, benzodiazepines are not indicated for the long-term treatment of anxiety, insomnia, or stress, for which they are most often prescribed [81–83].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [82]
In the citing paper
“Antipsychotics rapidly eliminated or rapidly dissociated from the D2 receptors (i.e., clozapine, quetiapine) [161, 162] are known to have greater risks of rebound when medication is decreased, switched, or discontinued [13, 154, 156, 157, 163].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [162]
In the citing paper
“In a systematic review, benzodiazepines were associated with fewer withdrawals and adverse events than AD in anxiety disorders.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
In the citing paper
“Such change has occurred without any supporting evidence.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
In the citing paper
“In panic disorder, whether accompanied by agoraphobia or not, benzodiazepine treatment was more effective in reducing the number of panic attacks than antidepressant medications.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Davis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,326
Research works printed but not linked: 1
- 10.1159%2f000334112 · DOI
Cited by
Items 101–195 of 195
Laurito, L. D., Loureiro, C. P., Dias, R. V., Vigne, P., de Menezes, G. B., Freire, R. C. R., Stangier, U., & Fontenelle, L. F. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.02.013 · Cited by 8
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025) · PLOS One · doi:10.1371/journal.pone.0330277 · Cited by 7
High-Dose Benzodiazepine Use among Long-Term Users: When Will We Ever Learn?
Zito, J. M. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000437374 · Cited by 7
Meng, L., Lin, C.-W. G., Chuang, H.-M., Chen, Y., Shang, C., Wu, C., Chen, L., & Hsiao, F. (2024) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5847 · Cited by 7
Fernandes, H., Novais, C., Sousa‐Pinto, B., Soares-da-Silva, P., & Azevedo, L. F. (2025) · Psychotherapy and Psychosomatics · doi:10.1159/000546269 · Cited by 7
Särkilä, H., Taipale, H. T., Tanskanen, A. J., Kurko, T., Taiminen, T. J., Tiihonen, J., Sund, R., Saastamoinen, L., Hietala, J. A., & Niemelä, S. (2024) · BJPsych Open · doi:10.1192/bjo.2024.780 · Cited by 6
Chapoutot, M., Meloni, F., Peter‐Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R. C., Nicolas, A., Higgins, S., Bourgeois, A., et al. (2025) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2025.100533 · Cited by 6
Analytical Methods used for the detection and quantification of benzodiazepinesPreprint
Qriouet, Z. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/4d8fw · Cited by 6
Lin, Y., Chen, M., Chang, Y., Chen, L., Hsiung, C. A., & Wu, S. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13678 · Cited by 5
Psychological dependence on antidepressants in patients with panic disorder: a cross-sectional study
Fujii, K., Suzuki, T., Mimura, M., & Uchida, H. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000143 · Cited by 5
Morbid Anxiety: Identification and Treatment
Goddard, A. W. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160046 · Cited by 5
Treatment-Resistant Panic Disorder
Chen, M., & Tsai, S. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_13 · Cited by 5
A pharmacological approach to panic disorder during pregnancy
Uğuz, F. (2015) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2015.1051025 · Cited by 5
Fava, G. A., Staccini, L., Chiaie, R. D., Belaise, C., & Tomba, E. (2014) · Rivista di psichiatria · doi:10.1708/1668.18270 · Cited by 5
Self-citationLooy, K. V., & de Velde, S. M. V. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00943-x · Cited by 4
Rodrigues‐Ribeiro, L., Resende, B. L., Dias, M. L. P., Lopes, M. R., de Barros, L. L. M., Moraes, M. A., Verano‐Braga, T., & Souza, B. R. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-50624-6_6 · Cited by 4
Fattahi, Y. Z., Kabiri, M., Rahimi, R., Khalilzadeh, R., & Karimi, M. (2021) · Iranian Red Crescent Medical Journal · doi:10.32592/ircmj.2021.23.12.1345 · Cited by 4
Plag, J., & Ströhle, A. (2020) · Springer eBooks · doi:10.1007/978-3-662-59038-6_13 · Cited by 4
Benzodiazepines in elderly patients
Fava, G. A. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13619 · Cited by 4
Self-citationPsychotropic Medication Use in the Elderly
Panini, A. D. C., Teves, M. R., Giraudo, E., Garraza, M. H., & Calderón, C. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-53126-7_22 · Cited by 3
Benzodiazepines: Kamo griadeshi?
Golovenko, M. Y. (2023) · JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE · doi:10.37621/jnamsu-2023-1-2-8 · Cited by 3
Unveiling Niaprazine’s Potential: Behavioral Insights into a Re-Emerging Anxiolytic Agent
Trebesova, H., Monaco, M. L., Baldassari, S., Ailuno, G., Lancellotti, E., Caviglioli, G., Pittaluga, A., & Grilli, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092087 · Cited by 3
Piccoli, E., Bergamaschini, I., Molteni, L., Vanzetto, S., Varinelli, A., Viganò, C. A., Catania, G., Baldwin, D. S., Domschke, K., & Dell’Osso, B. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000869 · Cited by 3
Юрьевич, О. Ю., Вобленко, Р. А., Арчаков, Д. С., & Александровна, Т. Е. (2016) · Современная терапия психических расстройств · Cited by 3
Consequences of a Missed History: A Case of Antidepressant Discontinuation Syndrome
Hameed, S., Kumar, M., Puri, P., Sapna, F., & Athwal, P. S. S. (2020) · Cureus · doi:10.7759/cureus.10950 · Cited by 3
Karl Rickels: A Tribute on His 90th Birthday
Bech, P. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357067 · Cited by 3
Eficácia dos benzodiazepínicos no tratamento de transtornos ansiosos: uma revisão de literatura
Ribeiro, G. L. D. J., & Brito, J. D. S. (2022) · Revista de Medicina · doi:10.11606/issn.1679-9836.v101i6e-194499 · Cited by 2
Benzodiazepines: Pharmacology Up-to-Date and Practical Issues
Kang, U. G., Kim, S. H., Lee, N. Y., Lee, K. Y., Kim, Y. S., & Chung, I. W. (2023) · 신경정신의학 · doi:10.4306/jknpa.2023.62.1.1 · Cited by 2
Somatovegetative Disorders in General Practice: an Algorithm for General Practitioners. A Review
Rachin, A. P., Charnukha, T., Madjidova, Y. N., Тлеубергеновна, Т. С., Turgumbaev, D. D., Смагулович, Н. Е., Djurabekova, A. T., Новикова, Л. Б., Chutko, L. S., Ekusheva, E. V., et al. (2025) · Comorbidity neurology · doi:10.62505/3034-185x-2025-2-1-62-73 · Cited by 2
Baldaçara, L., Veiga, D. D. L., Gaiotto, L. A. V., Paschoal, A. B., Pinto, A. F., Almeida, T. M., Santos, D. C. D., Loureiro, F. F., Malloy‐Diniz, L. F., Lacerda, A. L. T., et al. (2025) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2025-4349 · Cited by 2
Nakao, M., Morohoshi, H., Kurata, Y., & Nakamura, A. (2026) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.26.1407 · Cited by 2
Neuroscience-Informed Cognitive-Affective Training Interventions for Mood and Anxiety Disorders
Alvarez, E., & Iacoviello, B. M. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0049-2 · Cited by 2
The Characteristics of Benzodiazepine Prescribing in the Republic of Srpska, Bosnia and Herzegovina
Maksimović, Ž., Stajić, M., Stojiljković, M. P., Šatara, S. S., Stojaković, N., & Škrbić, R. (2022) · Medicina · doi:10.3390/medicina58080980 · Cited by 2
Balon, R. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000365043 · Cited by 2
La psichiatria di consultazione e collegamento: modelli e dati della letteratura
Fulcheri, M., Bellino, S., Zizza, M., Lorenzo, R. D., & Bogetto, F. (2001) · Rivista di psichiatria · doi:10.1708/184.1943 · Cited by 2
Estado actual del tratamiento de la ansiedad
Navarrete, F. F., & Gutiérrez, L. C. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70693-0 · Cited by 2
Lehti, V., Salama, E., Niemelä, S., Tanskanen, A. J., Gissler, M., Suvisaari, J., & Taipale, H. T. (2022) · Scandinavian Journal of Public Health · doi:10.1177/14034948221112470 · Cited by 2
Staging of Panic Disorder: Implications for Neurobiology and Treatment
Cosci, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-12538-1_5 · Cited by 1
Абрамова, Е. В., Воронин, М. В., & Середенин, С. Б. (2019) · Химико-фармацевтический журнал · doi:10.30906/0023-1134-2019-53-8-3-7 · Cited by 1
Plag, J., & Ströhle, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-65774-4_13 · Cited by 1
Medications for Anxiety Disorders
Narita, Z. C., Fujimoto, M., Winter, E., Nestadt, P. S., & Sawa, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_136-1 · Cited by 1
Ding, S., Li, Y., Chen, Z., Hu, J., Li, J., Li, J., & Wang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810165 · Cited by 1
Castaneda, J. M., Leonhard, A., Spece, L. J., Duan, K. I., Palen, B. N., Chen, J. A., Li, Y. I., Zeliadt, S. B., Josey, K., Feemster, L. C., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202407-798oc · Cited by 1
Garceau, L. (2023) · Corpus Université Laval (Université Laval) · Cited by 1
van Rangelrooij, K., Buxeda, R. S., Fernández-García, M. J., Caycedo-Desprez, N., Selvam, R. M., & Bulbena, A. (2020) · Actas Españolas de Psiquiatría · Cited by 1
The Popularity of Benzodiazepines, Their Advantages, and Inadequate Pharmacological Alternatives
Starčević, V. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3248 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Pollack, M. H., Stein, M. B., Simon, N. M., & Ameringen, M. V. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010048r
Chronic benzodiazepine use in nursing home residents: assessment of benefits and risks in insomnia
Bourgeois, J. (2014) · Ghent University Academic Bibliography (Ghent University)
Ärevushäirete psühhofarmakoloogia Schmiedebergist homseni
Harro, J. (2013) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.11378
Comparison of the anxiolytic effects of diazepam and kava on behaviour in rats.
Flynn, N. J. (2016) · UC Research Repository (University of Canterbury) · doi:10.26021/8950
Eficacia y seguridad de antipsicóticos en el síndrome confusional
Amigo, C., López, M., Ormaechea, G., & Tamosiunas, G. (2016) · Americanae (AECID Library) · Cited by 2
Changes in psychopharmacological management of persons with borderline personality disorder
Balon, R. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12779
Epidemiological studies of medication use and effectiveness in bipolar disorder
Wingård, L. (2017) · Figshare
Psychische und Verhaltensstörungen durch psychotrope Substanzen/Sucht und Substanzstörungen im Alter
Mühlig, S., & Wolter, D. K. (2017) · Elsevier eBooks · doi:10.1016/b978-3-437-24435-3.00008-5
Fava, G. A. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-76050-1.00016-7
Self-citationFava, G. A. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-76050-1.00017-9
Self-citationАбрамова, Е. В., Воронин, М. В., & Середенин, С. Б. (2019) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-019-02060-6
Valkenburg, C. V. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_24
Smith, C. M., & Riordan, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-94960-0_7
Psychotherapeutic interventions
Cosci, F., & Fava, G. A. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198746638.003.0018
Self-citationde Jongh, T. O. H., & van Heest, F. B. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-1922-0_42
Psychische und Verhaltensstörungen durch psychotrope Substanzen/Sucht und Substanzstörungen im Alter
Mühlig, S., & Wolter, D. K. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-24436-0.00017-7
Benkert, O. (2014) · Springer eBooks · doi:10.1007/978-3-642-54769-0_4
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as06
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as06
van Rangelrooij, K., Caycedo, N., Fernández-García, M.-J., Castell, S. L., & Bulbena, A. (2022) · HEGEL - HEpato-GastroEntérologie Libérale · doi:10.3917/heg.124.0334
АЛГОРИТМ БИОЛОГИЧЕСКОЙ ТЕРАПИИ ПАНИЧЕСКОГО РАССТРОЙСТВА
Потанин, С. С., Beburishvili, A. A., Гантман, М. В., Морозова, М. А., & Мосолов, С. Н. (2017) · Современная терапия психических расстройств · doi:10.21265/psyph.2017.42.6852
Arch, J. J., Kirk, A., & Craske, M. G. (2017) · Wiley eBooks · doi:10.1002/9781394258949.ch3
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd06
Cognitive-Behavioral Therapy Targeted to the Successful Discontinuation of Benzodiazepine Medication
Long, L. J., Parsons, E. M., & Otto, M. W. (2024) · CBT: science into practice · doi:10.1007/978-3-031-62971-6_10
Medications for Anxiety Disorders
Narita, Z. C., Fujimoto, M., Winter, E., Nestadt, P. S., & Sawa, A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_136
The use of medicinal plants in the treatment of anxiety
Dias, P. G. A., Gama, A. R., Machado, R. C., & do Nascimento-Silva, N. R. R. (2024) · Caderno Pedagógico · doi:10.54033/cadpedv21n13-239
Fava, G. A. (2025) · The International Library of Bioethics · doi:10.1007/978-94-024-2274-0_11
Self-citationA review of scientific evidence of pharmacological treatment for anxiety disorders
Santana, H. V. D. C. A., Silva, V., Silva, L. A. S., Santos, R. V. D. S., Souza, C. A. S., Barreto, D. M., Moreira, F. V., Rodrigues, I. D. S. V., & Souza, M. T. D. S. (2023) · Scire Salutis · doi:10.6008/cbpc2236-9600.2023.003.0001
Les manifestations cliniques du sevrage après arrêt des antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00002-9
Self-citationPrévention de la dépendance et de la symptomatologie du sevrage dus aux traitements antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00012-1
Self-citationRecent Advances in Benzodiazepine Electroanalysis
Cheregi, M. C., Iorgulescu, E. E., Comănescu, M.-A., David, I. G., & Trifu, A. S. (2025) · Chemosensors · doi:10.3390/chemosensors13090351
Романов, Д. В., & Sheyanov, A. M. (2025) · Современная терапия психических расстройств · doi:10.48612/psyph/48gk-56xv-b56b
Zamora Murillo, A. (2022) · Investigative News in Education (Universidad de Costa Rica)
Suvremeni farmakološki pristup liječenju anksioznih poremećaja
Antunica Povrženić, I. (2023) · Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)
Antidepresivi – istraživanja i primjena
Petrić, F. (2023) · University of Zagreb University Computing Centre (SRCE)
Oprea, M. (2022) · Papyrus : Institutional Repository (Université de Montréal)
Het optimaliseren van exposure behandeling: Sterktes en beperkingen van het extinctiemodel
Scheveneels, S. (2019) · Lirias
Stein, D. J., Kazdin, A. E., Baldwin, D. S., Harris, M., Hwang, I. H., Pozuelo, J. R., Sampson, N. A., Woodruff, P. W. R., Viana, M. C., Aguilar‐Gaxiola, S., et al. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70031
Leite, E. L. L. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Wijaya, A. F. S., Algristian, H., & Suwarti, A. S. (2026) · Medicor Journal of Health Informatics and Health Policy · doi:10.61978/medicor.v4i2.1174
Watt, J. A., Sharma, S., Huang, Y. Q., Jones, A., Nicholson, K., Yu, A. Y., Straus, S. E., DiPaolo, M. T., Kapral, M. K., & Vyas, M. V. (2026) · Age and Ageing · doi:10.1093/ageing/afag267
Anxiolytic and Potential Neurotoxic Effects of Salvia hypoleuca in Mice
Talebi, M., Alinejad, R., Naderi, N., & Mojab, F. (2025) · Iranian journal of pharmaceutical sciences · doi:10.22037/ijps.v21i1.47937
Sultania, B., Ahmed, I. A., Ghaffar, F., Bibi, N., & Akbar, S. (2025) · Dialogue Social Science Review (DSSR)
Fornaro, M., Lorenzo, C. D., Caldirola, D., & Perna, G. R. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122668
Metadata
- Authors
- Offidani, E., Guidi, J., Tomba, E., & Fava, G. A.
- Affiliations
- University of Bologna (IT)
- University at Buffalo, State University of New York (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 82
- Issue
- 6
- Pages
- 355-362
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2058854656
- Semantic Scholar
- 51250bb52dc9a5838fd9cb633760bcbf3bfe6a5e
- Cited by
- 166
- References
- 64
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 17 · 2023: 8 · 2022: 12 · 2021: 6 · 2020: 17 · 2019: 12 · 2018: 16 · 2017: 17 · 2016: 13 · 2015: 16 · 2014: 17 · 2013: 2
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- benzodiazepines, antidepressants, anxiety disorders, tricyclic antidepressants, panic disorder, generalized anxiety disorder, mixed anxiety-depressive disorder, treatment efficacy, tolerability, adverse events, treatment withdrawal, prescribing patterns
- MeSH terms
- Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety Disorders, Benzodiazepines, Humans, Obsessive-Compulsive Disorder, Practice Patterns, Physicians', Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.